Xenon Joins the Russell 3000® and Russell 2000® Indexes
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution, effective June 27, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution, effective June 27, 2025.
The Russell 3000® Index tracks the 3,000 largest U.S. stocks by market cap, while the Russell 2000® measures the 2,000 smallest companies within the Russell 3000®. These widely-used indexes serve as benchmarks for approximately $10.6 trillion in assets. The company's inclusion will result in automatic addition to corresponding growth and value style indexes.
Positive
- Inclusion in Russell 3000® and Russell 2000® Indexes increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index fund inclusion
- Access to broader investor base through automatic inclusion in growth and value style indexes
Negative
- None.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was -3.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025.
The Russell 3000® Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index. Inclusion in the Russell 2000® results in automatic inclusion in the appropriate growth and value style indexes.
Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately
For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.